Serum miRNA improves the accuracy of a multivariate index assay for triage of an adnexal mass.

Autor: Webber JW; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Wollborn L; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, MA, USA., Mishra S; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, MA, USA., Vitonis AF; Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham Women's Hospital, Boston, MA, USA., Cramer DW; Harvard Medical School, Boston, MA, USA; Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham Women's Hospital, Boston, MA, USA., Phan RT; Aspira Women's Health, Trumbull, CT, USA., Pappas TC; Aspira Women's Health, Trumbull, CT, USA., Stawiski K; Department of Biostatistics and Translational Medicine, Medical University of Łódź, Łódź, Poland., Fendler W; Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Biostatistics and Translational Medicine, Medical University of Łódź, Łódź, Poland., Chowdhury D; Harvard Medical School, Boston, MA, USA; Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Elias KM; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: kelias@bwh.harvard.edu.
Jazyk: angličtina
Zdroj: Gynecologic oncology [Gynecol Oncol] 2024 Aug 23; Vol. 190, pp. 124-130. Date of Electronic Publication: 2024 Aug 23.
DOI: 10.1016/j.ygyno.2024.08.008
Abstrakt: Objective: To determine whether a multimodal assay combining serum microRNA with protein biomarkers and metadata improves triage assessment of an adnexal mass.
Methods: Serum samples from 468 training subjects (191 cancer cases and 277 benign adnexal mass controls or healthy controls) were analyzed for seven protein biomarkers and 180 miRNA. Circulating analyte data were combined with age and menopausal status (metadata) into a neural network model to classify samples as cases or controls. Forward regression with ten-fold cross-validation minimized the dimensionality of the model while maximizing linear separation between cases and controls. Model validation proceeded using both internal (44 cases and 56 controls) and external validation sets (51 cases and 59 controls).
Results: The total study population comprised 678 subjects, including 286 cases and 392 controls. Overall, 290 (43%) of the subjects were premenopausal. A panel of 10 miRNA delivered optimal performance when combined with protein and metadata features. The combined model improved the Receiver Operator Characteristic Area Under the Curve (ROC AUC) on the internal (AUC = 0.9; 95% CI 0.81-0.95) and external validation sets (AUC = 0.95; 95% CI 0.90-0.98) compared to miRNA alone or proteins plus metadata (without miRNA). On external validation, the combined model offered 92% sensitivity at 80% specificity overall, with 80% and 100% sensitivity for early and late-stage cancers, respectively, including 78% sensitivity for early-stage, serous ovarian cancers and 82% sensitivity for early-stage, non-serous cancers.
Conclusions: A multimodal assay combining miRNA with protein biomarkers, age, and menopausal status improves surgical triage of an adnexal mass.
(Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: